Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Hypertension. 2003;42:787-792
Published online before print August 4, 2003, doi: 10.1161/01.HYP.0000085334.34963.4E
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
42/4/787    most recent
01.HYP.0000085334.34963.4Ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeng, C.
Right arrow Articles by Jose, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeng, C.
Right arrow Articles by Jose, P. A.
Related Collections
Right arrow Hypertension - basic studies

(Hypertension. 2003;42:787.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Perturbation of D1 Dopamine and AT1 Receptor Interaction in Spontaneously Hypertensive Rats

Chunyu Zeng; Yingjin Luo; Laureano D. Asico; Ulrich Hopfer; Gilbert M. Eisner; Robin A. Felder; Pedro A. Jose

From the Departments of Pediatrics (C.Z., Y.L., L.D.A., G.M.E., P.A.J.), Physiology and Biophysics (P.A.J.), and Internal Medicine (G.M.E.), Georgetown University Medical Center, Washington, DC; the Department of Physiology (U.H.), Case Western Reserve School of Medicine, Cleveland, Ohio; the Department of Pathology (R.A.F.), Virginia University for the Health Sciences, Charlottesville, Va; and the Department of Cardiology (C.Z.), Daping Hospital, Third Military Medical University, Chongqing, Peoples Republic of China.

Correspondence to Dr Chunyu Zeng, Department of Pediatrics, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007. E-mail cyzeng1{at}hotmail.com


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
The dopaminergic and renin-angiotensin systems interact to regulate blood pressure. Because this interaction may be perturbed in genetic hypertension, we studied D1 dopamine and AT1 angiotensin receptors in immortalized renal proximal tubule (RPT) and A10 aortic vascular smooth muscle cells. In normotensive Wistar-Kyoto (WKY) rats, the D1-like agonist fenoldopam increased D1 receptors but decreased AT1 receptors. These effects were blocked by the D1-like antagonist SCH 23390 (10-7 mol/L per 24 hours). In spontaneously hypertensive rat (SHR) RPT cells, fenoldopam also decreased AT1 receptors but no longer stimulated D1 receptor expression. Basal levels of AT1/D1 receptor coimmunoprecipitation were greater in WKY RPT cells (29±2 density units, DU) than in SHR RPT cells (21±2 DU, n=7 per group, P<0.05). The coimmunoprecipitation of D1 and AT1 receptors was increased by fenoldopam (10-7 mol/L per 24 hours) in WKY RPT cells but decreased in SHR RPT cells. The effects of fenoldopam in RPT cells from WKY rats were similar in aortic vascular smooth muscle cells from normotensive BD IX rats, that is, fenoldopam decreased AT1 receptors and increased D1 receptors. Our studies show differential regulation of the expression of D1 and AT1 receptors in RPT cells from WKY and SHR. This regulation and D1/AT1 receptor interaction are different in RPT cells of WKY and SHR. An altered interaction of D1 and AT1 receptors may play a role in the impaired sodium excretion and enhanced vasoconstriction in hypertension.


Key Words: hypertension, essential • receptors, angiotensin II • dopamine • kidney • muscle, smooth, vascular


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Dopamine, a neurotransmitter in neural tissue, acts as an autocrine/paracrine substance in nonneural tissues. Dopamine produced in neural and nonneural tissues is now recognized to serve an important role in the regulation of blood pressure and sodium balance by direct actions on renal and intestinal epithelial ion transport, by interaction with other receptors, by modulation of the secretion of hormonal/humoral agents such as aldosterone, catecholamines, renin, and vasopressin, and by actions on brain appetite centers.1 Dopamine receptors are classified into D1-like (D1, D5) and D2-like (D2, D3 and D4) subtypes, based on their structure and pharmacology. Whereas the D1-like receptors couple to the stimulatory G protein, G{alpha}S and thus, activate adenylyl cyclases, the receptors of the D2-like subfamily couple to the inhibitory G protein, G{alpha}i/G{alpha}O and inhibit adenylyl cyclases and calcium channels and modulate potassium channels.1–3 Under euvolemic conditions and magnified during moderate volume expansion, dopamine, through D1-like and D3 receptors, acts to increase sodium excretion and decrease blood pressure.1,4,5

The renin-angiotensin system is another important regulator of sodium transport and blood pressure.6 Like dopamine, angiotensin exerts its action through several receptor subtypes. AT1 receptors are linked to Gq/11 and G{alpha}i/G{alpha}O, whereas AT2 receptors are linked to G{alpha}i2/32,7; the G protein linkage of AT4 receptors is not clear.8 Although angiotensin, through AT2 and AT4 receptors, can decrease blood pressure by vasodilation and increase in sodium excretion, the major effect of angiotensin II is increasing sodium reabsorption and blood pressure, counteracting the effect of dopamine.6–10

Dopamine and angiotensin receptors counteract each other in the paracrine regulation of renal sodium transport. Thus, the natriuretic effect of D1-like receptors is enhanced when angiotensin II production is decreased or when AT1 receptors are blocked.11 Dopamine, through D1-like and D2-like receptors, by themselves or in concert, antagonizes the stimulatory actions of angiotensin II on proximal tubular luminal sodium transport. Dopamine, through D1-like receptors, also decreases AT1 receptor expression and angiotensin II binding sites in renal proximal tubules.12–15 D2-like receptors,14 and more specifically, the D3 receptor, also decrease AT1 receptor expression in immortalized renal proximal tubule (RPT) cells from normotensive Wistar-Kyoto (WKY) rats.16 Immortalized RPT cells have characteristics similar to freshly obtained RPTs and renal brush border membranes.17–20

Similar to the counterregulatory effects of these systems on renal sodium transport, the renal vasoconstrictor effect of angiotensin II is counteracted by the vasodilator action of dopamine, through D1-like receptors, in normotensive WKY rats.21,22 In spontaneously hypertensive rats (SHR), the renal vasodilatory effect of D1-like receptors is decreased and there is a lack of D1-like receptor antagonism of the vasoconstrictor effect of angiotensin II.21,22 Our previous study showed that angiotensin II increases D1 receptor expression in RPT cells from WKY rats but not from SHR.23 We hypothesize that there is a differential interaction of D1 and AT1 receptors not only in RPT cells but also in vascular smooth muscle cells of WKY and SHR. We now report that fenoldopam, an agonist for D1-like receptors (D1 and D5), increases expression of D1 receptors and decreases expression of AT1 receptors in RPT cells from WKY rats and A10 cells,24,25 a primary culture of vascular smooth muscle cells from the embryonic thoracic aorta of normotensive BD IX rats. The actions of fenoldopam are exerted through D1-like receptors because the effects are blocked by SCH23390, an antagonist for D1-like receptors (D1 and D5). Although D1/AT1 receptors physically interact in both cell lines, fenoldopam increases D1/AT1 receptor coimmunoprecipitation in RPT cells from WKY rats but decreases it in SHR. In SHR, fenoldopam no longer affects D1 receptor expression but its ability to decrease AT1 receptors is preserved; the effect of fenoldopam on AT1 receptor expression may be exerted through another D1-like receptor.1–3


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Cell Culture
Immortalized RPT cells from WKY and SHR and primary cultures of embryonic thoracic aortic smooth muscle cells (A10) (passage 10 to 20) from normotensive Berlin-Druckrey IX (BD IX) rats were cultured at 37°C in 95% air/5% CO2 atmosphere in DMEM/F-12 or DMEM, respectively.17,24,25 The cells (80% confluence) were extracted in ice-cold lysis buffer,17 sonicated, kept on ice for 1 hour, and centrifuged at 16 000g for 30 minutes. The supernatants were stored at -70°C until use.

Immunoblotting
The antibodies are polyclonal, purified antipeptides. The human AT1 receptor immunogenic peptide is QDDCPKAGRHC, amino acids 15 to 24 of the AT1 receptor. The rat D1 receptor antibody corresponds to positions 299 to 307 (GSEETQPFC) of the D1 receptor. The specificities of these antibodies have been reported.17–19,26–30 The cells were treated with vehicle (dH2O), fenoldopam, or a D1-like receptor antagonist (SCH23390) at the indicated concentrations and times. Immunoblotting was performed as reported17–20,26 except that the transblots were probed with the D1 (1:800) or the AT1 receptor antibody (1:400). Equality of total amount of protein per sample (50 µg) transferred onto the membranes was ascertained by Ponceau-S staining and by immunoblotting for {alpha}-actin.

Immunoprecipitation
RPT cells were incubated with vehicle or fenoldopam (10-7 mol/L) for 24 hours, as described above. The cells were lysed with ice-cold lysis buffer for 1 hour and centrifuged at 16 000g for 30 minutes. Supernatant (500 µg protein/mL) was incubated with affinity-purified rabbit anti-rat D1 receptor antibody (2 µL/mL) for 1 hour and protein-G agarose at 4°C for 12 hours. The immunoprecipitates were pelleted and washed 4 times with lysis buffer. The pellets were suspended in sample buffer, boiled for 10 minutes, and subjected to immunoblotting with the AT1 receptor antibody. To determine the specificity of the bands, preimmune serum of D1 receptor antibody (negative control) and AT1 receptor antibody (positive control) were used as immunoprecipitants instead of the D1 receptor antibody. The bands were quantified by densitometry.17–20,26

Materials
Rabbit anti-human AT1 receptor antibodies were purchased from Santa Cruz Biotechnology, Inc; D1 receptor antibodies were custom-produced (Research Genetics). Fenoldopam and SCH23390 were from Sigma. A10 cells were from ATCC. Other reagents were of the highest purity available (Sigma or Gibco).

Statistical Analysis
The data are expressed as mean±SEM. Comparisons within and among groups were made by repeated-measures and factorial ANOVA, respectively, with the Duncan test. A value of P<0.05 was considered significant.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Fenoldopam Decreases AT1 Receptor Expression in RPT Cells From WKY and SHR
Fenoldopam decreased AT1 receptor expression ({approx}45 kDa) in a concentration- and time-dependent manner in WKY RPT cells. The inhibitory effect was evident at 10-9mol/L, with a 50% decrease at 1.4x10-9mol/L (Figure 1A). The inhibitory effect of fenoldopam (10-7 mol/L) was noted as early as 8 hours and maintained for at least 30 hours (t1/2=15.5 hours) (Figure 1B). In SHR RPT cells, fenoldopam also decreased AT1 receptor expression (WKY: control=31±1, fenoldopam (10-7mol/L)=21±1 density units, [DU]; SHR: control=27±2, fenoldopam (10-7 mol/L) =20±2 DU; n=8/group), (Figure 1C).



View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Effect of D1-like agonist fenoldopam on AT1 receptor expression in RPT cells from WKY and SHR. A and B, Concentration-response (24 hours) and time course (10-7 mol/L) of AT1 receptor expression ({approx}45 kDa), determined by immunoblotting, in RPT cells from WKY rats treated with fenoldopam. All immunoblotting results are expressed as relative density units (DU) (n=7 to 10, *P<0.05 vs control [C], ANOVA, Duncan test). One immunoblot is depicted in the inset. C, Effects of fenoldopam (10-7 mol/L per 24 hours) on AT1 receptor expression in RPT cells from WKY and SHR. Cells were incubated at indicated times and concentrations (n=8, *P<0.05 vs control, ANOVA, Duncan test). One immunoblot is depicted in the inset. D, Effects of fenoldopam (Fen) and a D1-like receptor antagonist (SCH23390, SCH) on AT1 receptor expression in RPT cells from WKY rats. Cells were incubated with the indicated reagents (fenoldopam, 10-7 mol/L; SCH23390, 10-7 mol/L) for 24 hours (n=9, *P<0.05 vs others, ANOVA, Duncan test). One immunoblot is depicted in the inset. The apparent molecular size of the AT1 receptor ({approx}45 kDa) is in agreement with our previous report.17

The specificity of fenoldopam as a D1-like receptor agonist was determined by studying the effect of the D1-like receptor antagonist SCH23390. In WKY RPT cells, consistent with the study shown in Figures 1A and 1B, fenoldopam (10-7mol/L per 24 hours) decreased AT1 receptor expression (control=26±2 DU, fenoldopam=19±2 DU; n=9, P<0.05). SCH23390 (10-7 mol/L) by itself had no effect (28±2 DU) but reversed the inhibitory effect of fenoldopam on AT1 receptor expression (28±3 DU) (Figure 1D). In SHR RPT cells, SCH23390 also blocked the inhibitory effect of fenoldopam on AT1 receptor expression (control=29±3 DU, fenoldopam=16±3 DU, SCH23390=28±4, SCH23390+ fenoldopam=29±3; n=12, P<0.05).

Fenoldopam Increases D1 Receptor Expression in RPT Cells From WKY Rats But Not From SHR
To investigate the effect of fenoldopam on the D1 receptor, RPT cells were incubated with fenoldopam (10-7 mol/L) for 24 hours. Fenoldopam increased D1 receptor expression ({approx}80 kDa) in RPT cells from WKY rats (control=25±3 DU, fenoldopam=37±3 DU; P<0.05, n=8) but had no significant effect in cells from SHR (control=22±2 DU, fenoldopam=17±4 DU; n=8/group) (Figure 2A).



View larger version (30K):
[in this window]
[in a new window]
  		Figure 2. A, Different effect of fenoldopam on D1 receptor expression in RPT cells from WKY and SHR. Cells were incubated with indicated reagents (fenoldopam, 10-7 mol/L) for 24 hours (n=8, *P<0.05 vs others, ANOVA, Duncan test). One immunoblot is depicted in the inset. The major D1 receptor had a molecular size of {approx}80 kDa.18,19 B, Effects of fenoldopam (Fen) and a D1-like receptor antagonist (SCH23390, SCH) on D1 receptor expression in RPT cells from WKY rats. Cells were incubated with indicated reagents (fenoldopam, 10-7 mol/L; SCH23390, 10-7 mol/L) for 24 hours (n=11, *P<0.05 vs others, ANOVA, Duncan test). One immunoblot is depicted in the inset.

The specificity of fenoldopam as a D1-like receptor agonist also was determined by studying the effect of the D1-like receptor antagonist SCH23390 on D1 receptor protein expression. In WKY RPT cells, consistent with the study shown in Figure 2A, fenoldopam (10-7 mol/L per 24 hours) increased D1 receptor expression (control=22±1 DU, fenoldopam=30±2 DU; n=11, P<0.05). SCH23390 (10-7 mol/L) by itself had no effect (24±2 DU) but reversed the stimulatory effect of fenoldopam on D1 receptor expression (24±3 DU) (Figure 2B).

Fenoldopam Increases D1 Receptors and Decreases AT1 Receptors in A10 Cells
To test our hypothesis that the effects of fenoldopam on AT1 and D1 receptors happens not only in RPT cells but also in vascular smooth muscle cells, A10 cells were treated with fenoldopam at the indicated concentrations and times. In A10 cells, as in RPT cells, fenoldopam decreased AT1 receptors and increased D1 receptors (D1: EC50=1.0x10-9mol/L, t1/2=16.0 hours; AT1: EC50=5.1x10-10 mol/L, t1/2=16.1 hours) in a time-dependent (2 to 30 hours) and concentration-dependent (10-11 to 10-5 mol/L) manner (D1 receptor: Figures 3A and 3B; AT1 receptor: data not shown). In A10 cells, as in RPT cells, fenoldopam exerted its effects on D1-like receptors; SCH23390 completely blocked the effect of fenoldopam on AT1 receptor expression (Figure 4).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. Effect of fenoldopam on D1 receptor expression in A10 cells. A and B, Concentration response (24 hours) and time course (10-7 mol/L) of D1 receptor expression, determined by immunoblotting, in A10 cells treated with fenoldopam. All immunoblotting results are expressed as relative density units (DU) (n=6 to 7, *P<0.05 vs control [C], ANOVA, Duncan test). One immunoblot is depicted in the inset. Major D1 receptor had a molecular size of {approx}80 kDa.18,19



View larger version (28K):
[in this window]
[in a new window]
  		Figure 4. Effect of fenoldopam (Fen) and SCH23390 (SCH) on AT1 receptor expression in A10 cells. Cells were incubated with the indicated reagents (fenoldopam, 10-7 mol/L; SCH23390, 10-7 mol/L) for 24 hours (n=13, *P<0.05 vs others, ANOVA, Duncan test). One immunoblot is depicted in the inset.

AT1 Receptor Coimmunoprecipitates With the D1 Receptor in Rat RPT Cells
To determine whether there is a physical interaction between the D1 and the AT1 receptor, additional experiments were performed. D1 receptors were first immunoprecipitated with anti-D1 receptor antibodies and then probed with anti-AT1 receptor antibodies. As shown in Figure 5A, basal coimmunoprecipitation was greater in RPT cells from WKY rats than those in SHR (45-kDa bands represented the coimmunoprecipitated D1 and AT1 receptors). The 24-hour treatment of fenoldopam (10-7 mol/L) increased D1/AT1 coimmunoprecipitation in RPT cells from WKY rats but decreased it in SHR (WKY: control=29±2 DU, fenoldopam=39±2 DU; n=7, P<0.05; SHR: control=21±2 DU, fenoldopam=11±1 DU; n=7, P<0.05). The changes in D1/AT1 coimmunoprecipitation caused by fenoldopam were blocked by 10-7 mol/L SCH23390 (n=2) (Figure 5B).



View larger version (38K):
[in this window]
[in a new window]
  		Figure 5. A, Effect of fenoldopam on the coimmunoprecipitation of D1 and AT1 receptors in rat RPT cells. Cells were incubated with fenoldopam (10-7 mol/L) for 24 hours. Thereafter, samples were immunoprecipitated with anti–D1 receptor antibodies and immunoblotted with anti–AT1 antibodies (#P<0.05 vs control, *P<0.05, vs WKY, n=7, ANOVA, Duncan test). One immunoblot ({approx}45 kDa) is depicted in the inset: (lane 1=positive control, lane 2=negative control, lane 3=vehicle-treated RPT cell of WKY rats, lane 4=fenoldopam-treated RPT cell of WKY rats, lane 5=vehicle-treated RPT cell of SHR, lane 6=fenoldopam-treated RPT cell of SHR). For positive control, anti–AT1 antibodies (1 µg/mL) were used as immunoprecipitant; for negative control, preimmune serum of D1 receptor (2 µL/mL) was used as immunoprecipitant instead of anti–D1 receptor antibodies and immunoblotted with anti–AT1 receptor antibodies as above. B, Effect of fenoldopam (Fen) and SCH23390 (SCH) on D1/AT1 receptor coimmunoprecipitation in rat RPT cells from SHR and WKY rats. Cells were incubated with the indicated reagents (fenoldopam, 10-7 mol/L; SCH23390, 10-7 mol/L) for 24 hours (n=2). One immunoblot is shown.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
There are several novel observations in our study. First, we show that the D1-like receptor agonist fenoldopam increases D1 receptor expression but decreases AT1 receptor expression in RPT cells from WKY rats. This effect is exerted at the D1 receptor because a D1-like receptor antagonist, SCH23390, completely blocks the effect of fenoldopam. Second, in SHR, although fenoldopam also decreases AT1 receptor expression, it has no effect on D1 receptor expression. Third, AT1 receptors coimmunoprecipitate with D1 receptors in rat RPT cells. The basal level of AT1/D1 coimmunoprecipitation is greater in WKY than in SHR. Moreover, fenoldopam increases the physical interaction between AT1 and D1 receptors in rat RPT cells from WKY rats but decreases it in SHR. Fourth, the stimulatory effect of fenoldopam on D1 receptor expression and inhibitory effect on AT1 receptor in RPT cells from WKY rats also occur in A10 cells.

Both dopamine and renin-angiotensin systems exist in the RPT.1,3,6,13 The components of the renin-angiotensin system, including angiotensinogen mRNA, renin, and ACE, have been localized the proximal tubule.6,13,31,32 The proximal tubule is also the site of local dopamine production.1,33 Urinary dopamine and angiotensin II concentrations exceed circulating levels, suggesting that both systems may modulate RPT function in an autocrine or paracrine function.6,13,31,33–35 Dopamine and angiotensin II are two important regulators of sodium and water absorption in the kidney serving counteracting functions in the proximal tubule. Low concentrations of angiotensin II stimulate net reabsorption through activation of Na+/H+ exchanger-3, Na+-HCO3 cotransporter, and Na+-K+ATPase,6,12–14,36,37 whereas dopamine exerts the opposite effect.1,3,14,19,37–41 Salt depletion increases angiotensin II production and AT1 receptor expression in renal proximal tubules in normotensive rats, resulting in increased reabsorption of sodium and water.6,13 Conversely, sodium loading increases the production of dopamine, which by activation of D1- and D2-like receptors, promotes renal sodium and water excretion.1,3,33,34

The current study shows that long-term D1-like receptor stimulation (hours) increases D1 receptors and decreases AT1 receptors both in RPT from WKY rats17 and in A10 vascular smooth muscle cells from normotensive BD IX rats.24 This may be a mechanism by which D1-like receptors continue to exert their effects long after D1 receptor desensitization should have occurred.42–44 The inhibitory effect of the D1-like receptor on sodium transport has been consistent,1,3,14,19,37–41 whereas its effect on resistance vessels has not been so.1 Thus, although most studies have reported a vasorelaxant effect of D1-like receptors,1,3,42 a vasoconstriction effect has been reported in the rat tail artery.45 In our study, we found that fenoldopam increased D1 receptor expression in A10 cells but decreased AT1 receptor expression. These effects together with a D1-like receptor-induced increase in cAMP levels should lead to vasodilation in resistance vessels, at least in the normotensive state.

We found a direct interaction between AT1 and D1 receptors by immunoprecipitation study. The basal level of AT1/D1 coimmunoprecipitation is much higher in WKY rats as compared with SHR. D1 receptor stimulation with fenoldopam results in an increase in the coimmunoprecipitation of AT1 and D1 receptors in WKY rats, whereas a decrease occurs in SHR. The increase in AT1/D1 coimmunoprecipitation in WKY rats could have been caused by the increase in D1 receptor expression per se or an increased physical interaction between AT1 and D1 receptors. We favor the latter because D1 receptor expression in SHR RPT cells is not affected by fenoldopam, yet the AT1/D1 receptor coimmunoprecipitation is still decreased. It is possible that the D1 receptors antagonize AT1 receptor function in WKY rats by sequestering AT1 receptors. In SHR, the defective D1 receptor is unable to perform this function, allowing more AT1 receptors to respond to angiotensin II. Whether this differential D1/AT1 interaction in WKY and SHR has functional consequences remains to be determined. Further studies are also needed to determine whether the increased interaction between these two receptors is a direct or an indirect mechanism, possibly by the alteration of an adaptor gene or adaptor proteins. Others have shown that several G protein–coupled receptors are known to interact directly with each other by homo- or hetero-oligomerization.46,47 Thus, an adaptor protein for D2 and D3 receptors (protein 4.1N) has been recently identified that is important in their localization in plasma membranes.48

It is known that the D1-like receptor function is impaired in the renal proximal tubule and medullary thick ascending limb of genetically hypertensive rats, such as the SHR.1,3 The impaired D1-like receptor function is not caused by abnormalities in G proteins or effectors proteins but rather the D1-like receptor is uncoupled from its G protein/effector complex because of increased activity of the G protein–coupled receptor kinase type 4.1,49 Therefore, it is not unexpected that the ability of the D1-like receptor agonist to increase D1 receptor expression in WKY rats is no longer present in SHR. However, the persistence of the ability of D1-like receptor stimulation to inhibit AT1 receptor expression in RPT cells of SHR is unexpected. Because there are two D1-like receptors expressed in RPT cells,1,3 we hypothesize that the effect of D1-like agonist stimulation may have been exerted at the other D1-like receptor, the D5 receptor, which remains functional in the SHR. Our preliminary data show that in D5 knockout mice, AT1 receptor expression is higher in the renal cortical membrane as compared with its wild-type control animals (C. Zeng, J.E. Jones, L.D. Asico, and P.A. Jose, unpublished data, 2003). Because the increase in cAMP levels after D1-like receptor stimulation is due mainly to D1 receptor rather than D5 receptor effect,50 we presume that the inhibitory effect of D5 receptors on AT1 receptor expression may not have a significant impact on overall D1-like receptor function mediated by cAMP in the kidney of normotensive animals.

In mesangial, renal proximal tubular, vascular smooth muscle, and adrenocortical cells, increasing intracellular cAMP levels decreases steady state AT1 receptor expression.11,13,51–53 Since the 5' promoter region of rat AT1 receptor expression has a cAMP response element, further studies will be required to determine whether cAMP decreases receptor expression by transcriptional and/or posttranscriptional mechanisms. We have reported that D1-like receptors can inhibit NHE3 activity independent of cAMP, through G{alpha}S.19 The linkage between D1 and D5 receptors to G protein subunits are different. Thus, the D5 receptor (but not the D1 receptor) is linked to G{alpha}12 and G{alpha}13.28 Gß1 and G{gamma}7 transduce D1 (but not D5) receptor function.54 It is therefore possible that the regulation of AT1 receptors by D1-like receptors can occur by cAMP-independent and G protein subunit–dependent mechanisms.

In summary, we have demonstrated that the D1-like agonist fenoldopam positively regulates the expression of D1 receptors and negatively regulates AT1 receptors in vascular smooth muscle and RPT cells from normotensive rats. Whereas fenoldopam does not stimulate D1 receptor expression in SHR RPT cells, the inhibitory effect on AT1 receptor expression is seen. AT1 and D1 receptors physically interact with each other; fenoldopam increases the interaction between these two G protein–coupled receptors in WKY RPT cells but decreases it in SHR RPT cells.

Perspectives
The dopaminergic and renin-angiotensin systems are two important systems that regulate blood pressure. Dopamine causes natriuresis and vasorelaxation, whereas angiotensin II leads to opposite effects.1,3–6,12–14,19,36–41 The major D1-like receptor subtype mediating the increase in sodium excretion is probably the D1 receptor,1,3,50 whereas the major angiotensin II receptor mediating the decrease in renal sodium excretion is the AT1 receptor.6–10 In SHR, renal proximal tubular D1 receptor function is impaired.4 It is possible that the increased renal vascular resistance and increased renal sodium transport in SHR6,37,55 are caused by a defective interaction between D1 and AT1 receptors. However, which is primary and which is secondary remains to be determined.


*    Acknowledgments
 
These studies were supported in part by grants from the National Institutes of Health, HL-23081, DK-39308, HL-68686, DK-52612, HL-62211, and HL-41618.

Received May 12, 2003; first decision May 27, 2003; accepted June 26, 2003.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in health and hypertension. Pharmacol Ther. 1998; 80: 149–182.[CrossRef][Medline] [Order article via Infotrieve]
  2. Jose PA, Eisner GM, Felder RA. Dopamine receptor-coupling defect in hypertension. Curr Hypertens Rep. 2002; 4: 237–244.[Medline] [Order article via Infotrieve]
  3. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension. 1998; 32: 187–197.[Abstract/Free Full Text]
  4. Ladines CA, Zeng C, Asico LD, Sun X, Pocchiari F, Semeraro C, Pisegna J, Wank S, Yamaguchi I, Eisner GM, Jose PA. Impaired renal D1-like and D2-like dopamine receptor interaction in the spontaneously hypertensive rat. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R1071–R1078.[Abstract/Free Full Text]
  5. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, Jose PA. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest. 1998; 102: 493–498.[Medline] [Order article via Infotrieve]
  6. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002; 39: 316–322.[Abstract/Free Full Text]
  7. Inagami T, Kambayashi Y, Ichiki T, Tsuzuki S, Eguchi S, Yamakawa T. Angiotensin receptors: molecular biology and signalling. Clin Exp Pharmacol Physiol. 1999; 26: 544–549.[CrossRef][Medline] [Order article via Infotrieve]
  8. Handa RK. Characterization and signaling of the AT4 receptor in human proximal tubule epithelial (HK-2) cells. J Am Soc Nephrol. 2001; 12: 440–449.[Abstract/Free Full Text]
  9. Haithcock D, Jiao H, Cui XL, Hopfer U, Douglas JG. Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol. 1999; 10 (suppl 11): S69–S74.[Medline] [Order article via Infotrieve]
  10. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension. 2001; 38: 1272–1277.[Abstract/Free Full Text]
  11. Chen C, Lokhandwala MF. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Naunyn Schmiedebergs Arch Pharmacol. 1995; 352: 194–200.[Medline] [Order article via Infotrieve]
  12. Hussain T, Abdul-Wahab R, Kotak DK, Lokhandwala MF. Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension. 1998; 32: 1054–1059.[Abstract/Free Full Text]
  13. Harris RC, Becker BN, Cheng HF. Acute and chronic mechanisms for regulating proximal tubule angiotensin II receptor expression. J Am Soc Nephrol. 1997; 8: 306–313.[Medline] [Order article via Infotrieve]
  14. Sheikh-Hamad D, Wang YP, Jo OD, Yanagawa N. Dopamine antagonizes the actions of angiotensin II in renal brush-border membrane. Am J Physiol. 1993; 264: F737–F743.[Medline] [Order article via Infotrieve]
  15. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1996; 97: 2745–2752.[Medline] [Order article via Infotrieve]
  16. Zeng C, Yu P, Zheng S, Eisner GM, Jose PA. D3 Dopamine receptors positively regulate D1 dopamine receptor and negatively regulate AT1 angiotensin receptor. J Am Soc Nephrol. 2001; 12: 477A.
  17. Zeng C, Asico LD, Wang X, Hopfer U, Eisner GM, Felder RA, Jose PA. Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension. 2003; 41: 724–729.[Abstract/Free Full Text]
  18. Xu J, Li XX, Albrecht FE, Hopfer U, Carey RM, Jose PA. D1 receptor, Gs{alpha}, and Na+/H+ exchanger interactions in the kidney in hypertension. Hypertension. 2000; 36: 395–399.[Abstract/Free Full Text]
  19. Albrecht FE, Xu J, Moe OW, Hopfer U, Simonds WF, Orlowski J, Jose PA. Regulation of NHE3 activity by G protein subunits in renal brush-border membranes. Am J Physiol Regul Integr Comp Physiol. 2000; 278: R1064–R1073.[Abstract/Free Full Text]
  20. Yu P-Y, Asico LD, Eisner GM, Hopfer U, Felder RA, Jose PA. Renal protein phosphatase 2A activity and spontaneous hypertension in rats. Hypertension. 2000; 36: 1053–1058.[Abstract/Free Full Text]
  21. Chatziantoniou C, Ruan X, Arendshorst WJ. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc Natl Acad Sci U S A. 1995; 92: 2924–2928.[Abstract/Free Full Text]
  22. de Vries PA, Navis G, de Jong PE, de Zeeuw D, Kluppel CA. Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1999; 34: 191–198.[CrossRef][Medline] [Order article via Infotrieve]
  23. Zeng C, Yu P, Asico LD, Eisner GM, Jose PA. AT1 angiotensin receptors lose the ability to upregulate D1 dopamine receptors in renal proximal tubule cells from spontaneously hypertensive rats. J Am Soc Nephrol. 2002; 13: 148. Abstract.
  24. Iso T, Chung G, Hamamori Y, Kedes L. HERP1 is a cell type-specific primary target of Notch. J Biol Chem. 2002; 277: 6598–6607.[Abstract/Free Full Text]
  25. Kimes BW, Brandt BL. Characterization of two putative smooth muscle cell lines from rat thoracic aorta. Exp Cell Res. 1976; 98: 349–366.[CrossRef][Medline] [Order article via Infotrieve]
  26. Sanada H, Jose PA, Hazen-Martin D, Yu PY, Xu J, Bruns DE, Phipps J, Carey RM, Felder RA. Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension. 1999; 33: 1036–1042.[Abstract/Free Full Text]
  27. O’Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA, Carey RM. Localization of dopamine D1A receptor protein in rat kidneys. Am J Physiol. 1995; 268: F1185–F1197.[Medline] [Order article via Infotrieve]
  28. Zheng S, Yu P, Zeng C, Wang Z, Yang Z, Andrews PM, Felder RA, Jose PA. Galpha12- and Galpha13-protein subunit linkage of D5 dopamine receptors in the nephron. Hypertension. 2003; 41: 604–610.[Abstract/Free Full Text]
  29. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS III, Westphal H, Jose PA, Sibley DR. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci. 2002; 22: 10801–10810.[Abstract/Free Full Text]
  30. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE, Ooi GT, Grinberg A, Lee EJ, Huang SP, Bartlett PF, Jose PA, Sibley DR, Westphal H. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci U S A. 1994; 91: 12564–12568.[Abstract/Free Full Text]
  31. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest. 1990; 86: 1352–1357.[Medline] [Order article via Infotrieve]
  32. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule: an hypothesis for the intrarenal renin angiotensin system. J Clin Invest. 1990; 85: 417–423.[Medline] [Order article via Infotrieve]
  33. Soares-da-Silva P. Source and handling of renal dopamine: its physiological importance. News Physiol Sci. 1994; 9: 128–134.[Abstract/Free Full Text]
  34. Wang ZQ, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine production and distribution in the rat: physiological control of sodium excretion. Hypertension. 1997; 29: 228–234.[Abstract/Free Full Text]
  35. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest. 1990; 86: 1352–1357.[Medline] [Order article via Infotrieve]
  36. Horita S, Zheng Y, Hara C, Yamada H, Kunimi M, Taniguchi S, Uwatoko S, Sugaya T, Goto A, Fujita T, Seki G. Biphasic regulation of Na+-HCO3- cotransporter by angiotensin II type 1A receptor. Hypertension. 2002; 40: 707–712.[Abstract/Free Full Text]
  37. Ortiz PA, Garvin JL. Intrarenal transport and vasoactive substances in hypertension. Hypertension. 2001; 38: 621–624.[Abstract/Free Full Text]
  38. Kunimi M, Seki G, Hara C, Taniguchi S, Uwatoko S, Goto A, Kimura S, Fujita T. Dopamine inhibits renal Na+:HCO3- cotransporter in rabbits and normotensive rats but not in spontaneously hypertensive rats. Kidney Int. 2000; 57: 534–543.[CrossRef][Medline] [Order article via Infotrieve]
  39. Aperia A, Holtback U, Syren ML, Svensson LB, Fryckstedt J, Greengard P. Activation/deactivation of renal Na+, K+-ATPase: a final common pathway for regulation of natriuresis. FASEB J. 1994; 8: 436–439.[Abstract]
  40. Efendiev R, Yudowski GA, Zwiller J, Leibiger B, Katz AI, Berggren PO, Pedemonte CH, Leibiger IB, Bertorello AM. Relevance of dopamine signals anchoring dynamin-2 to the plasma membrane during Na+, K+-ATPase endocytosis. J Biol Chem. 2002; 277: 44108–44114.[Abstract/Free Full Text]
  41. Hu MC, Fan L, Crowder LA, Karim-Jimenez Z, Murer H, Moe OW. Dopamine acutely stimulates Na+/H+ exchanger (NHE3) endocytosis via clathrin-coated vesicles: dependence on protein kinase A-mediated NHE3 phosphorylation. J Biol Chem. 2001; 276: 26906–26915.[Abstract/Free Full Text]
  42. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, King B, Carey RM. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension. 1988; 11: I-69–I-74.[Medline] [Order article via Infotrieve]
  43. Gardner B, Liu ZF, Jiang D, Sibley DR. The role of phosphorylation/dephosphorylation in agonist-induced desensitization of D1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation. Mol Pharmacol. 2001; 59: 310–321.[Abstract/Free Full Text]
  44. Watanabe H, Xu J, Bengra C, Jose PA, Felder RA. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int. 2002; 62: 790–798.[CrossRef][Medline] [Order article via Infotrieve]
  45. Rashed SM, Songu-Mize E. Regulation of Na+-pump activity by dopamine in rat tail arteries. Eur J Pharmacol. 1995; 284: 289–297.[CrossRef][Medline] [Order article via Infotrieve]
  46. Nimchinsky EA, Hof PR, Janssen WG, Morrison JH, Schmauss C. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J Biol Chem. 1997; 272: 29229–29237.[Abstract/Free Full Text]
  47. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 2000; 407: 94–98.[CrossRef][Medline] [Order article via Infotrieve]
  48. Binda AV, Kabbani N, Lin R, Levenson R. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol. 2002; 62: 507–513.[Abstract/Free Full Text]
  49. Felder RA, Sanada H, Xu J, Yu P, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A. 2002; 99: 3872–3877.[Abstract/Free Full Text]
  50. Sanada H, Xu J, Watanabe H, Jose PA, Felder RA. Differential expression and regulation of dopamine-1 (D-1) and dopamine-5 (D-5) receptor function in human kidney. Am J Hypertens. 2000; 13: 156A. Abstract.
  51. Makita N, Iwai N, Inagami T, Badr KF. Two distinct pathways in the down-regulation of type-1 angiotensin II receptor gene in rat glomerular mesangial cells. Biochem Biophys Res Commun. 1992; 185: 142–146.[CrossRef][Medline] [Order article via Infotrieve]
  52. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995; 48: 601–609.[Abstract]
  53. Bird IM, Mason JI, Rainey WE. Regulation of type 1 angiotensin II receptor messenger ribonucleic acid expression in human adrenocortical carcinoma H295 cells. Endocrinology. 1994; 134: 2468–2474.[Abstract]
  54. Wang Q, Jolly JP, Surmeier JD, Mullah BM, Lidow MS, Bergson CM, Robishaw JD. Differential dependence of the D1 and D5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylylcyclase. J Biol Chem. 2001; 276: 39386–39393.[Abstract/Free Full Text]
  55. Thomas D, Harris PJ, Morgan TO. Age-related changes in angiotensin II-stimulated proximal tubule fluid reabsorption in the spontaneously hypertensive rat. J Hypertens. 1988; 6 (suppl 4): S449–S451.



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, and K. Okumura
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization
Cardiovasc Res, July 1, 2008; 79(1): 169 - 178.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Zeng, V. A. M. Villar, G. M. Eisner, S. M. Williams, R. A. Felder, and P. A. Jose
G Protein-Coupled Receptor Kinase 4: Role in Blood Pressure Regulation
Hypertension, June 1, 2008; 51(6): 1449 - 1455.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose
Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H551 - H569.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. J. Gildea, X. Wang, P. A. Jose, and R. A. Felder
Differential D1 and D5 Receptor Regulation and Degradation of the Angiotensin Type 1 Receptor
Hypertension, February 1, 2008; 51(2): 360 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Mogi, M. Iwai, and M. Horiuchi
Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2532 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. L. Cook, S. J. Mills, R. T. Naquin, J. Alam, and R. N. Re
Cleavage of the angiotensin II type 1 receptor and nuclear accumulation of the cytoplasmic carboxy-terminal fragment
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1313 - C1322.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
P. K. Mehta and K. K. Griendling
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Sanada, J. Yatabe, S. Midorikawa, T. Katoh, S. Hashimoto, T. Watanabe, J. Xu, Y. Luo, X. Wang, C. Zeng, et al.
Amelioration of Genetic Hypertension by Suppression of Renal G Protein-Coupled Receptor Kinase Type 4 Expression
Hypertension, June 1, 2006; 47(6): 1131 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Zeng, Z. Wang, H. Li, P. Yu, S. Zheng, L. Wu, L. D. Asico, U. Hopfer, G. M. Eisner, R. A. Felder, et al.
D3 Dopamine Receptor Directly Interacts With D1 Dopamine Receptor in Immortalized Renal Proximal Tubule Cells
Hypertension, March 1, 2006; 47(3): 573 - 579.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. J. Bek, X. Wang, L. D. Asico, J. E. Jones, S. Zheng, X. Li, G. M. Eisner, D. K. Grandy, R. M. Carey, P. Soares-da-Silva, et al.
Angiotensin-II Type 1 Receptor-Mediated Hypertension in D4 Dopamine Receptor-Deficient Mice
Hypertension, February 1, 2006; 47(2): 288 - 295.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Zeng, U. Hopfer, L. D. Asico, G. M. Eisner, R. A. Felder, and P. A. Jose
Altered AT1 Receptor Regulation of ETB Receptors in Renal Proximal Tubule Cells of Spontaneously Hypertensive Rats
Hypertension, October 1, 2005; 46(4): 926 - 931.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Zeng, Z. Wang, U. Hopfer, L. D. Asico, G. M. Eisner, R. A. Felder, and P. A. Jose
Rat Strain Effects of AT1 Receptor Activation on D1 Dopamine Receptors in Immortalized Renal Proximal Tubule Cells
Hypertension, October 1, 2005; 46(4): 799 - 805.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
Y.-H. Feng, Y. Ding, S. Ren, L. Zhou, C. Xu, and S. S. Karnik
Unconventional Homologous Internalization of the Angiotensin II Type-1 Receptor Induced by G-Protein-Independent Signals
Hypertension, August 1, 2005; 46(2): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page